Clinical Trial Search

Primary: Number of Participants With Breast Cancer Recurrence, Including Recurrent DCIS and New Contralateral Tumours — 103; 120 Participants — p=0.33

Primary: Number of Participants With Imaging Data Collected — 249; 1 Participants

Primary: Number of Participants With a Change in Ki-67 Level — 15; 5; 3 Participants — p=0.004

Primary: Impact of US-guided DOT on the Potential Reduction of Benign Biopsies as Measured by Comparing the Reads With a Non- Suspicious Assessment of Conventional Imaging (CI)…

Primary: Change in Isothiocyanate in Urine Samples as Assessed at Baseline and After Completion of Study Therapy — 1.00; -0.05 µM/mM creatinine

Primary: Number of Participants Analysed for Reduction in Lump Size ( 60% Reduction in Lump Size Considered to be a Satisfactory Response) — 63; 61; 54; 14 participants

Primary: Proportion of Women Who Benefited of Performing Upfront Sentinel Lymph Node (SLN) Biopsy Ductal Carcinoma in Situ — 51 Participants

Primary: Change in Proliferation Rate (Ki-67 by Immunocytochemistry) From Baseline to 6 Months — -1.5; -1.1 percentage of cells stained positive — p=0.92

Primary: Median Change in 6-month Tumor Volume Compared to Baseline Using Mammography — -5.0 change in tumor volume (mm) — p=0.07

Primary: Quality of Life as Measured by the Breast Q — 61.9; 57.6; 74.2; 64.2 score on a scale

Primary: Change in Masood Score — -1.1; -0.8 units on a scale

Primary: Correlation of Peak Displacement (PD) for Detecting Malignancy — 4.5803; 8.628 microns — p=0.2988

Primary: Number of Participants for Which DBT Altered Surgical Plan — 0 Participants

Primary: Percentage of Patients Free From Breast Cancer — 89.1; 93.1 percentage of participants event-free

Primary: Mean Total MRI Functional Tumor Volume (FTV) Change From Baseline to Month 3 (V3) — -1.93 cubic centimeters — p=<0.001

Primary: Rate of Detection of Invasive Cancers — 9; 14 Participants

Primary: 18F-FES Uptake in DCIS — 1.43 SUV

Primary: Feasibility for a Larger Trial — 42; 28; 28 Participants

Primary: Local Control Using Ipsilateral Breast Tumor Recurrence Rates — .7 percentage of participants

Primary: Number of Participants With Adverse Events Greater Than Grade 2 Serious Toxicity Rate, Defined as Toxicity Greater Than Grade 2 Using Common Terminology Criteria for…

Primary: Pathologic Complete Response Rate After Preoperative Therapy in This Patient Population. — 8; 44 percentage of participants

Primary: The Negative Predictive Value (PVV) of MRI

Primary: Number of Patients With Pathological Complete Response — 2 participants

Primary: Recall Rate in Group A Participants — 29; 34; 472; 467 Participants — p=0.46

Primary: Cancer Yield Per 1,000 — 5.0; 6.3; 4.9; 5.9 Cancer yield per 1,000 — p=0.005

Primary: Number of Participants Without Cancer Who Were Recalled — 274 participants

Primary: Difference Between Ki-67 Labeling Index in Tissue Samples Taken at Baseline and Post-treatment — -3.4; -5.1 percentage of 300 DCIS cells

Primary: Change in Ki-67 in Breast Tissue of High-Risk Women

Primary: Postoperative Duration of Drain Placements — 9.2; 10.8 days — p=0.15

Primary: Breast Cup Immobilization Device II (GCC 1047) Feasibility — 25 Participants